Myelofibrosis
A Phase 2 Study of the Safety, Tolerability, and Efficacy of INCB050465 in Combination With Ruxolitinib in Subjects With Myelofibrosis
The purpose of this study is to evaluate the safety, tolerability, and efficacy of the combination of INCB050465 and ruxolitinib in subjects with myelofibrosis
Talk to your doctor if you are interested in participating in this study.
To find a study center near you, call 855-463-3463, then select option 1.
You can also visit clinicaltrials.gov and enter NCT02718300 to learn more.
https://clinicaltrials.gov/ct2/results?term=NCT02718300&Search=Search
Essential Thrombocythemia
A Double-Blind, Double-Dummy Phase 2 Randomized Study to Evaluate the Efficacy and Safety of Ruxolitinib Versus Anagrelide in Subjects With Essential Thrombocythemia Who Are Resistant to or Intolerant of Hydroxyurea (RESET-272)
The purpose of this study is to evaluate the efficacy and safety of ruxolitinib versus anagrelide in subjects with essential thrombocythemia who are resistant to or intolerant of hydroxyurea.
Talk to your doctor if you are interested in participating in this study.
To find a study center near you, call 855-463-3463, then select option 1.
You can also visit clinicaltrials.gov and enter NCT03123588 to learn more.
https://clinicaltrials.gov/ct2/results?term=NCT03123588&Search=Search
